Print
Email
Strategic collaborations play a vital role in fueling the growth of the biosimilar market. As the pharmaceutical industry continues to evolve, biosimilars have emerged as an essential component of healthcare systems worldwide, offering more affordable treatment options for various chronic and complex diseases. According to BioIntel360, the global biosimilar market size is expected to record a CAGR of 26.2% during 2023-2027 to reach US$51 billion by 2027, increasing from US$20 billion in 2023. Over the last five years, the sector has recorded a CAGR of 28.0% to reach US$16 billion in 2022.
Developing biosimilars involves substantial financial and regulatory risks. Collaborating with a partner can help mitigate some of these risks by sharing the financial burden and leveraging the partner's risk management expertise. For instance,
Alvotech, an Iceland-based biopharmaceutical company, has been facing financial challenges despite generating $16 million from the sales of its Humira biosimilar in Europe and Canada during the first quarter of 2023. The company is unable to maintain a steady financial position despite allocating $73 million on research and development and general expenses, particularly after its most recent FDA rejection in June.
However, a reworked partnership with Israeli generics company, Teva, holds promise for Alvotech's prospects and market expansion.
The Teva Deal: A Ray of Hope
As part of a strategic deal, Teva, a leading player in the generics industry, has stepped in to support Alvotech. The new agreement outlines "increased involvement" by Teva in the manufacturing and quality processes at Alvotech's facility in Iceland. Teva's support aims to ensure that Alvotech is well-prepared for an FDA inspection, a crucial step toward gaining approval for its biosimilars in the United States.
Along with manufacturing assistance, the agreement has grown to now encompass U.S. rights for two additional pipeline initiatives and line extensions for two previously unannounced biosimilars. This extension of rights opens up new opportunities for Alvotech in the U.S. market, which is vital for the company's long-term financial sustainability.
Alvotech's delay in launching its Humira biosimilar in the U.S. market due to the missed deadline in July has proven to be a significant setback. The U.S. market has already witnessed the launch of several other Humira biosimilars, and major insurers have included products from other competitors in their formularies, leaving Alvotech with a smaller window of opportunity to penetrate the market.
Moreover, the competition in the biosimilars space is intense, with multiple players vying for market share. BioIntel360 predicts that with the entry of additional biosimilars into the market, there is a high likelihood of a decline in the price and sales potential of these drugs. This scenario poses an even greater challenge for Alvotech in its quest to establish a competitive edge.
Despite the challenges, the partnership with Teva presents Alvotech with a renewed sense of hope. Teva's expertise in the generics market and its strong presence in the U.S. pharmaceutical industry can prove to be invaluable in navigating the complex regulatory landscape and market competition.
However, Alvotech must act quickly to resubmit its application for evaluation to the FDA. The six-month review period will be critical for the company's future, and a successful approval can pave the way for significant revenue generation in the U.S. market.
Alvotech's financial struggles and recent FDA rejection have placed the company at a critical juncture. The partnership with Teva offers a glimmer of hope, providing manufacturing support, and granting access to new pipeline projects and line extensions for existing biosimilars. However, competition in the biosimilars market is fierce, and Alvotech must act decisively to reapply for FDA approval and seize the opportunity to establish its presence in the U.S. market. With determination and the support of its strategic partner, Alvotech can overcome its financial challenges and solidify its position in the global biosimilars market. As the company continues its journey, investors will be closely watching the developments and their impact on Alvotech's financial performance and market presence.
